NVPDPP728 inhibits human and rat plasma DPP-IV (IC 50 s: 5-10 nM) with >15 000-fold selectivity relative to DPP-II and a range of proline-cleaving proteases[1].

NVP-DPP728 (3.72 mg/kg; p.o.) inhibits DPP-IV and improves insulin secretion and glucose tolerance, probably through augmentation of the effects of endogenous GLP-1[2]. Animal Model: Obese (fa/fa) and lean (FA/?) Zucker rats[2]Dosage: 3.72 mg/kg Administration: Oral administration Result: Led to inhibition of plasma DPP-IV activity.